PVR and neoplasm: Treatment of different tumor cell types with epigenetic drugs, like histone deacetylase inhibitors (HDACi) and DNA-methyltransferase inhibitors (DNMTi) (25–27, 39–43), leads to the upregulation of NKG2DLs and PVR surface levels, although it downregulates B7-H6 expression (44).